How AI errors in dosage and drug interactions could harm patients

New research suggests that the growing role of artificial intelligence (AI) in medication management may carry underexamined risks with potentially severe consequences for patient safety.

A new study by Khalid Adnan Alsayed brings this issue into sharp focus, arguing that current evaluation approaches overlook the most critical question in healthcare AI: what happens when the system gets it wrong. The research shifts attention away from traditional performance benchmarks toward real-world reliability, highlighting the dangers of relying on aggregate accuracy metrics in high-stakes medical contexts.

Published as "When AI Gets it Wrong: Reliability and Risk in AI-Assisted Medication Decision Systems," the study examines how AI systems perform under failure conditions and what types of errors emerge in medication-related decision-making. Through simulated pharmacy scenarios, it provides a structured analysis of how incorrect AI outputs translate into clinical risks and patient harm.

Hidden risks emerge as AI errors expose limits of performance-based evaluation

The study identifies a fundamental gap between how AI systems are evaluated and how they function in real clinical environments. While many systems demonstrate high accuracy under controlled testing conditions, these metrics fail to capture how models behave in complex, unpredictable scenarios common in healthcare.

AI-assisted medication systems are widely used across prescribing, dispensing, and monitoring processes, often supporting decisions related to drug interactions and dosage levels. These systems are designed to improve efficiency and reduce human error. However, the research shows that strong performance metrics such as accuracy and precision can create a false sense of reliability, masking underlying vulnerabilities in system behavior.

One of the key issues lies in variability. AI systems may produce inconsistent outputs when faced with small changes in patient data, drug combinations, or clinical context. In medication management, such inconsistencies can lead to different recommendations for similar cases, increasing the risk of undetected errors.

Another major concern is the lack of transparency in many AI models. Often operating as black-box systems, these tools provide recommendations without clear explanations, making it difficult for healthcare professionals to understand the reasoning behind decisions. This opacity limits the ability of clinicians and pharmacists to identify potential errors before they affect patient care.

The study notes that traditional evaluation frameworks are insufficient because they focus on overall performance rather than failure behavior. In safety-critical domains like pharmacy, even rare errors can have life-threatening consequences. As a result, assessing how and why systems fail becomes more important than measuring how often they succeed.

False negatives and dosage errors pose the greatest threat to patient safety

The study classifies error types in AI-assisted medication systems, revealing that not all errors carry equal risk. The findings show that certain failure modes, particularly false negatives and incorrect dosage recommendations, are far more dangerous than others.

False negatives occur when the system fails to identify a real risk, such as a harmful drug interaction. In medication contexts, this type of error can lead to severe adverse drug reactions without any warning, creating a false sense of safety for both clinicians and patients. According to the simulated evaluation, false negatives were the most frequent error type, highlighting a critical vulnerability in AI-assisted decision-making.

Missed interactions appeared more often than other error types, reinforcing their significance as the most dangerous category of system failure. These findings align with broader clinical safety research, which shows that undetected risks often result in more severe outcomes than overly cautious decisions.

Incorrect dosage recommendations represent another major risk. AI systems must account for multiple patient-specific variables, including age, weight, and medical history, when determining appropriate dosages. Even minor inaccuracies can lead to overdose, toxicity, or ineffective treatment. The study's simulated scenarios demonstrate how both overestimation and underestimation of dosage can have serious clinical consequences.

False positives, while less immediately harmful, also pose challenges. These errors occur when a system incorrectly flags a safe medication as risky, leading to unnecessary changes in treatment plans. Although they may not directly harm patients, they can delay care, reduce treatment effectiveness, and increase the complexity of clinical workflows.

A structured table presented on page 6 outlines multiple simulated scenarios, showing how different types of errors manifest in real-world situations. For example, cases where AI labeled dangerous drug combinations as safe resulted in false negatives, while incorrect dosage suggestions led to either overdose or ineffective treatment. This detailed breakdown highlights the uneven distribution of risk across different error types and underscores the importance of prioritizing high-impact failures in system evaluation.

Overreliance on AI and lack of transparency amplify clinical risks

Apart from technical limitations, the study identifies human and systemic factors that amplify the risks associated with AI-assisted medication systems. One of the most significant concerns is overreliance on AI recommendations by healthcare professionals.

With AI tools becoming more integrated into clinical workflows, there is a growing tendency for users to trust system outputs without sufficient verification. This phenomenon, often referred to as automation bias, can reduce critical oversight and increase the likelihood that errors go unnoticed. When systems appear highly accurate, clinicians may assume correctness even in cases where the output is flawed.

The problem is compounded by the lack of explainability in many AI systems. Without clear insight into how decisions are made, healthcare professionals may struggle to assess the validity of recommendations. This creates a situation where incorrect outputs are not only accepted but also difficult to challenge.

The study also highlights that reliability is not solely a technical property but a product of interaction between humans and AI systems. Even a highly accurate model can become unsafe if its limitations are not well understood or if users misinterpret its outputs. This interaction-driven perspective shifts the focus from isolated system performance to real-world usability and decision-making dynamics.

In addition, the research points to broader structural challenges in evaluating AI systems. Current practices often fail to account for the severity and distribution of errors, focusing instead on average performance. This approach obscures critical risks, particularly in cases where a small number of high-impact errors can outweigh overall system benefits.

To address these issues, the study calls for a shift toward reliability-focused evaluation frameworks. These frameworks should analyze failure types, error frequency, and clinical impact, providing a more comprehensive understanding of system behavior in real-world contexts.

Toward safer AI integration in pharmacy practice

While AI-assisted systems offer clear benefits in improving efficiency and supporting clinical workflows, their deployment must be accompanied by safeguards that address reliability and risk.

One of the key recommendations is the need for continued human oversight. AI systems should not be used as standalone decision-makers, especially in high-risk scenarios involving drug interactions and dosage determination. Instead, they should function as support tools that augment, rather than replace, clinical judgment.

The study also calls for a rethinking of evaluation practices. Traditional performance metrics must be complemented with analyses of failure behavior, focusing on how errors occur and what their consequences are. This includes prioritizing high-risk error types such as false negatives and dosage errors, which have the greatest potential for harm.

Improving transparency and interpretability is another critical priority. AI systems that provide clear explanations for their recommendations enable healthcare professionals to better understand and validate outputs. This not only enhances trust but also supports more informed and responsible decision-making.

Lastly, the research highlights the importance of safety-oriented design. Future AI systems should incorporate mechanisms for uncertainty estimation, fail-safe behavior, and risk-aware alerts, ensuring that potential errors are flagged and mitigated before they impact patient care.